Trigone

Trigone Pharma Announces a Strategic Collaboration with 4C Biomed to Develop a Novel Treatment for High-Grade Bladder Cancer

Retrieved on: 
Monday, September 20, 2021
AUA, HVEM, Patent, Bladder cancer, American Urological Association, Solution, Therapy, TNFRSF14, Cancer, Patient, IC/BPS, PCT, MD, Trigone, InterAction Council of Former Heads of State and Government, Immune system, Immunotherapy, CEO, Mab, Urinary bladder, Science, BTLA, MBA, Drug development, Pharming, D, Urologic disease, NMIBC, Epithelium, HSV, GLOBE, Pharmaceutical industry, Vaccine, Medical imaging

RAANANA, Israel, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Trigone Pharma (Trigone), a pharmaceutical company pioneering prolonged intravesical treatment combined with targeted therapies for the treatment of bladder cancer, today announced a collaboration with 4C Biomed, to develop an innovative treatment for bladder cancer.

Key Points: 
  • RAANANA, Israel, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Trigone Pharma (Trigone), a pharmaceutical company pioneering prolonged intravesical treatment combined with targeted therapies for the treatment of bladder cancer, today announced a collaboration with 4C Biomed, to develop an innovative treatment for bladder cancer.
  • The collaboration will focus on local administration of 4C Biomeds anti 4CB-1 as an innovative treatment for high-grade non-muscle invasive bladder cancer.
  • Trigone Pharma, a pharmaceutical company dedicated to developing novel solutions that treat bladder cancers and urologic diseases, and 4C Biomed, an early-stage biomed R&D group specializing in immuno-oncology and auto-immunity today announced a strategic collaboration agreement to advance novel intravesical immunotherapy, which is delivered directly into the bladder, for the treatment of high-grade non-muscle invasive bladder cancer (HG-NMIBC).
  • Trigone Pharma is dedicated to developing and commercializing novel therapeutics to treat patients suffering from interstitial cystitis/bladder pain syndrome (IC/BPS), bladder cancer (NMIBC), and other related bladder conditions.

Trigone Pharma to Present Preclinical Data for TRG-100 in Interstitial Cystitis / Bladder Pain Syndrome at the Upcoming American Urological Association Conference (AUA) in September 2021

Retrieved on: 
Thursday, July 22, 2021
Medical specialties, Anatomy, Urinary bladder disorders, Urology, Interstitial cystitis, Trigone, Urinary bladder, Overactive bladder, Renal colic

IC/BPS and its associated pain significantly affects quality of life, including loss of work, and is associated with suicidal rates five-to-seven times the national average.

Key Points: 
  • IC/BPS and its associated pain significantly affects quality of life, including loss of work, and is associated with suicidal rates five-to-seven times the national average.
  • Our preliminary results should be further confirmed in the upcoming Phase IIa trial, said Dan Touitou, Chief Executive Officer of Trigone Pharma.
  • The data has also prompted us to evaluate the safety and efficacy in overactive bladder and renal colic patients.
  • Trigone Pharma is aiming to restore the quality of life for patients suffering from bladder diseases that affect populations with unmet medical needs.